Indaptus Therapeutics Net Working Capital Over Time
| INDP Stock | USD 1.02 0.01 0.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Indaptus Therapeutics Performance and Indaptus Therapeutics Correlation. Indaptus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Indaptus Therapeutics. If investors know Indaptus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Indaptus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Return On Assets (0.71) | Return On Equity (1.27) |
The market value of Indaptus Therapeutics is measured differently than its book value, which is the value of Indaptus that is recorded on the company's balance sheet. Investors also form their own opinion of Indaptus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Indaptus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Indaptus Therapeutics' market value can be influenced by many factors that don't directly affect Indaptus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Indaptus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Indaptus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Indaptus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Working Capital Analysis
Compare Indaptus Therapeutics and related stocks such as Rezolute, Tempest Therapeutics, and Comera Life Sciences Net Working Capital Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RZLT | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | (4.2 M) | 3.8 M | 7.3 M | 40 M | 149.6 M | 99.7 M | 119 M | 125 M |
| TPST | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 48.9 M | 25.7 M | 31 M | 33.6 M |
| FBRX | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 57.6 M | 40.8 M | 38.3 M | 34.7 M | 38.9 M |
| ABVC | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (5.5 M) | (5.9 M) | 1.3 M | 5.9 M | (2.8 M) | (4.3 M) | (4.1 M) |
| KTTA | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 241.4 K | 52.9 M | 32.2 M | 14.1 M | 27.3 M |
| NTRB | 121.5 K | 121.5 K | 121.5 K | 121.5 K | 121.5 K | 121.5 K | 121.5 K | 121.5 K | 187.5 K | (2 M) | (2.3 M) | 4.7 M | 1.9 M | 22.8 K | 21.6 K |
| QNRX | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (7.5 M) | (201.6 K) | 9.8 M | 7.7 M | 8.1 M |
| LGVN | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | (115.8 K) | (2 M) | 32.7 M | 15.4 M | 2 M | 1.9 M |
| RNXT | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (2.2 M) | 15.3 M | 6.2 M | 291 K | 276.4 K |
| VRAX | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (831.8 K) | (1.2 M) | 8.7 M | 4.2 M | 2.1 M |
| REVB | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | (229.6 K) | 962.3 K | 6.6 M | 6.9 M |
| KPRX | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | 4.6 M | 2.9 M | 37.8 K | 7.4 M | 4.4 M | 3.1 M | 2.5 M |
| ANEB | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 15.1 M | 10.6 M | 10.6 M | 3.2 M | 3.1 M |
| ASMB | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 109.6 M | 204 M | 258.3 M | 200.1 M | 138.1 M | 80.7 M | 94.6 M | 124 M |
Indaptus Therapeutics and related stocks such as Rezolute, Tempest Therapeutics, and Comera Life Sciences Net Working Capital description
My Equities
My Current Equities and Potential Positions
| Indaptus Therapeutics | INDP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 1.02
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.